Develops proprietary patient-specific cell therapeutics for stem cell tissue repair, and the treatment of cancer and infectious disease.

MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies that lead to the reproducible creation of highly functional cell lines.

Cryo-Save is the leading family umbilical cord blood stem cell bank in Europe by stem cell samples with over 60.000 stored. Cryo-Save is not involved in any kind of commercialisation or manipulation of stem cells for therapeutic purposes and is only storing adult stem cells

Endovasc’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. It also holds licenses and patents for the treatment of vascular dysfunction related to heart disease.

Geron is focused on developing and commercializing therapeutic and diagnostic products for cancer based on our telomerase technology, and cell-based therapeutics using our human embryonic stem cell technology.

PharmaGap Inc. is a biotechnology company with a core focus discovering and developing novel therapeutic drugs for the treatment of cancer. Founded in 1999, the Company is a spin-off out of Canada’s pre-eminent biological research organization, the National Research Council (NRC). PharmaGap’s unique research and drug development platform is a result of almost 10 years and $10 million of funded research by NRC scientists.

Transition Therapeutics Inc. is a publicly traded biopharmaceutical company developing novel approaches and therapeutics for the treatment of diabetes, multiple sclerosis (MS), hepatitis C, Alzheimer's disease, and restenosis.Islet neogenesis is the process by which islet cells are formed from stem cells in the pancreatic duct during fetal development.